Maze Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Maze Therapeutics Inc Unternehmen

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Maze Therapeutics Inc Informationen



BörsenkürzelMAZE

Name des UnternehmensMaze Therapeutics Inc

IPO-datumJan 31, 2025

CEOColoma (Jason V)

Anzahl der mitarbeiter125

WertpapierartOrdinary Share

GeschäftsjahresendeJan 31

Addresse171 Oyster Point Boulevard, Suite 300

StadtSOUTH SAN FRANCISCO

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl94080

Telefon16508505070

Websitehttps://www.mazetx.com/

BörsenkürzelMAZE

IPO-datumJan 31, 2025

CEOColoma (Jason V)

Führungskräfte von Maze Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Jonathan E. Lim, M.D.

Independent Director

328.70K

--

Dr. Sekar (Sek) Kathiresan, M.D.

Independent Director

103.72K

--

Mr. Atul Dandekar

Chief Strategy and Business Officer

23.25K

+61.54%

Dr. Charles Homcy, M.D.

Co-Founder, Director

--

Dr. Jason V. Coloma, Ph.D.

Chief Executive Officer, Director

--

Dr. Harold Bernstein, M.D., Ph.D.

President - Research and Development, Chief Medical Officer

--

Ms. Courtney J. Phillips

General Counsel, Corporate Secretary

--

Dr. Nancy C. Andrews, M.D., Ph.D.

Independent Director

--

Dr. Jamie Brush, M.D.

Independent Director

--

Mr. Alan B. Colowick, M.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Jonathan E. Lim, M.D.

Independent Director

328.70K

--

Dr. Sekar (Sek) Kathiresan, M.D.

Independent Director

103.72K

--

Mr. Atul Dandekar

Chief Strategy and Business Officer

23.25K

+61.54%

Dr. Charles Homcy, M.D.

Co-Founder, Director

--

Dr. Jason V. Coloma, Ph.D.

Chief Executive Officer, Director

--

Dr. Harold Bernstein, M.D., Ph.D.

President - Research and Development, Chief Medical Officer

--

Umsatzaufteilung

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2024

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach RegionUSD

Name

Umsatz

Anteil

United States

0.00

0.00%

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sun, May 10

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Third Rock Ventures, LLC

9.80%

Frazier Life Sciences Management, L.P.

8.25%

Deep Track Capital LP

7.67%

ARCH Venture Partners

7.44%

Janus Henderson Investors

5.68%

Andere

61.15%

Aktionäre

Anteil

Third Rock Ventures, LLC

9.80%

Frazier Life Sciences Management, L.P.

8.25%

Deep Track Capital LP

7.67%

ARCH Venture Partners

7.44%

Janus Henderson Investors

5.68%

Andere

61.15%

Aktionärstypen

Aktionäre

Anteil

Venture Capital

29.53%

Hedge Fund

22.51%

Investment Advisor/Hedge Fund

17.37%

Investment Advisor

14.65%

Private Equity

9.43%

Individual Investor

1.48%

Family Office

0.89%

Research Firm

0.69%

Bank and Trust

0.06%

Andere

3.39%

Institutionelle Beteiligung



Aktualisiert: Wed, Apr 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

213

53.41M

97.33%

+12.39M

2025Q4

156

40.80M

84.78%

+941.72K

2025Q3

111

39.53M

83.57%

-194.63K

2025Q2

100

42.58M

97.22%

+13.88M

2025Q1

93

44.69M

102.04%

+15.27M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Third Rock Ventures, LLC

5.42M

10.91%

--

Dec 31, 2025

Frazier Life Sciences Management, L.P.

4.57M

9.19%

--

Dec 31, 2025

Deep Track Capital LP

4.25M

8.54%

+297.53K

+7.53%

Dec 31, 2025

ARCH Venture Partners

4.12M

8.29%

--

Dec 31, 2025

Janus Henderson Investors

3.14M

6.32%

+2.39M

+317.97%

Dec 31, 2025

Andreessen Horowitz

1.70M

3.42%

--

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

1.64M

3.31%

+439.68K

+36.53%

Dec 31, 2025

VR Adviser, LLC

1.55M

3.12%

+317.80K

+25.82%

Dec 31, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

Virtus LifeSci Biotech Clinical Trials ETF

1.64%

Invesco Dorsey Wright SmallCap Momentum ETF

0.53%

ALPS Medical Breakthroughs ETF

0.39%

iShares Micro-Cap ETF

0.12%

iShares Russell 2000 Value ETF

0.04%

ProShares UltraPro Russell2000

0.03%

ProShares Hedge Replication ETF

0.03%

iShares Russell 2000 ETF

0.02%

Proshares Ultra Russell 2000

0.02%

Schwab U.S. Small-Cap ETF

0.02%

Virtus LifeSci Biotech Clinical Trials ETF

Anteil1.64%

Invesco Dorsey Wright SmallCap Momentum ETF

Anteil0.53%

ALPS Medical Breakthroughs ETF

Anteil0.39%

iShares Micro-Cap ETF

Anteil0.12%

iShares Russell 2000 Value ETF

Anteil0.04%

ProShares UltraPro Russell2000

Anteil0.03%

ProShares Hedge Replication ETF

Anteil0.03%

iShares Russell 2000 ETF

Anteil0.02%

Proshares Ultra Russell 2000

Anteil0.02%

Schwab U.S. Small-Cap ETF

Anteil0.02%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten